237 related articles for article (PubMed ID: 22245216)
1. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
Sircar K; Huang H; Hu L; Cogdell D; Dhillon J; Tzelepi V; Efstathiou E; Koumakpayi IH; Saad F; Luo D; Bismar TA; Aparicio A; Troncoso P; Navone N; Zhang W
Am J Pathol; 2012 Mar; 180(3):895-903. PubMed ID: 22245216
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.
Yu Q; Wang X; Wang L; Zheng J; Wang J; Wang B
Scand J Gastroenterol; 2016 Oct; 51(10):1220-6. PubMed ID: 27251594
[TBL] [Abstract][Full Text] [Related]
3. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
Nishikawa G; Kawada K; Hanada K; Maekawa H; Itatani Y; Miyoshi H; Taketo MM; Obama K
Cells; 2022 Oct; 11(20):. PubMed ID: 36291140
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
5. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
[TBL] [Abstract][Full Text] [Related]
6. The edited UPF1 is correlated with elevated asparagine synthetase in pancreatic ductal adenocarcinomas.
Hu J; Wang Z; Yang S; Lu Y; Li G
Mol Biol Rep; 2022 May; 49(5):3713-3720. PubMed ID: 35129766
[TBL] [Abstract][Full Text] [Related]
7. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
8. Integrated Bioinformatics Analysis Identified ASNS and DDIT3 as the Therapeutic Target in Castrate-Resistant Prostate Cancer.
Jung AR; Shin S; Kim MY; Ha US; Hong SH; Lee JY; Kim SW; Chung YJ; Park YH
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474084
[TBL] [Abstract][Full Text] [Related]
9. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Lorenzi PL; Reinhold WC; Rudelius M; Gunsior M; Shankavaram U; Bussey KJ; Scherf U; Eichler GS; Martin SE; Chin K; Gray JW; Kohn EC; Horak ID; Von Hoff DD; Raffeld M; Goldsmith PK; Caplen NJ; Weinstein JN
Mol Cancer Ther; 2006 Nov; 5(11):2613-23. PubMed ID: 17088436
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional induction of the human asparagine synthetase gene during the unfolded protein response does not require the ATF6 and IRE1/XBP1 arms of the pathway.
Gjymishka A; Su N; Kilberg MS
Biochem J; 2009 Feb; 417(3):695-703. PubMed ID: 18840095
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer.
Yang H; He X; Zheng Y; Feng W; Xia X; Yu X; Lin Z
Chem Biol Drug Des; 2014 Nov; 84(5):578-84. PubMed ID: 24775638
[TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
13. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
[TBL] [Abstract][Full Text] [Related]
14. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
15. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
16. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
17. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
18. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin.
Cui H; Darmanin S; Natsuisaka M; Kondo T; Asaka M; Shindoh M; Higashino F; Hamuro J; Okada F; Kobayashi M; Nakagawa K; Koide H; Kobayashi M
Cancer Res; 2007 Apr; 67(7):3345-55. PubMed ID: 17409444
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
